Capstone Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capstone Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$2.91M	Sell	22,598 -2,830	-11%	-$341K	0.08%	291
2017 Q1	$2.78M	Buy	25,428 +230	+0.9%	+$20.2K	0.08%	305
2016 Q4	$1.86M	Buy	25,198 +907	+4%	+$73.8K	0.05%	407
2016 Q3	$2.12M	Buy	24,291 +460	+2%	+$43.5K	0.06%	375
2016 Q2	$2.05M	Buy	23,831 +830	+4%	+$71.7K	0.06%	376
2016 Q1	$1.83M	Buy	23,001 +930	+4%	+$84.1K	0.05%	421
2015 Q4	$2.78M	Buy	22,071 +2,231	+11%	+$269K	0.08%	299
2015 Q3	$2.07M	Buy	19,840 +1,175	+6%	+$151K	0.06%	356
2015 Q2	$2.31M	Buy	18,665 +2,498	+15%	+$315K	0.07%	346
2015 Q1	$1.91M	Buy	16,167 +390	+2%	+$46.7K	0.05%	404
2014 Q4	$1.87M	Sell	15,777 -7,210	-31%	-$812K	0.05%	396
2014 Q3	$2.58M	Buy	22,987 +190	+0.8%	+$18.1K	0.09%	273
2014 Q2	$2.16M	Sell	22,797 -3,021	-12%	-$212K	0.07%	321
2014 Q1	$1.83M	Sell	25,818 -2,550	-9%	-$202K	0.06%	390
2013 Q4	$2.11M	Sell	28,368 -12,838	-31%	-$894K	0.06%	364
2013 Q3	$3.12M	Buy	41,206 +6,890	+20%	+$548K	0.08%	300
2013 Q2	$2.75M	Buy	+34,316	New	+$2.53M	0.07%	311

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capstone Asset Management's VRTX Position: Q2 2017 in Review

Capstone Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2017, selling an estimated $341K and leaving 22,598 shares worth $2.91M. The position accounts for 0.08% of the portfolio, ranked #291.

Capstone Asset Management first reported a position in VRTX in Q2 2013 and has held it in 17 quarters since. The position peaked at $3.12M in Q3 2013. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

Capstone Asset Management held 22,598 shares of Vertex Pharmaceuticals worth $2.91M as of Q2 2017.
Capstone Asset Management sold 2,830 Vertex Pharmaceuticals shares in Q2 2017, an estimated $341K.
Vertex Pharmaceuticals made up 0.08% of Capstone Asset Management's portfolio in Q2 2017, its #291 holding.
Capstone Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Capstone Asset Management's Vertex Pharmaceuticals position peaked at $3.12M in Q3 2013.
582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.